The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry

Table 6 Comparison of lung functions and their time trends in NIN patients with different GAP index at baseline

All data are given as:	GAP I	GAP II	GAP III	P¹
mean (95% CI), p-value	N = 174	N = 160	N = 22	P¹
Annual rate of change
FVC (l/yr)	-0.007 (-0.05; 0.036), p = 0.750	0.004 (-0.043; 0.052), p = 0.863	-0.173 (-0.314; -0.032), p = 0.016	p = 0.068
DLco (mmol/kPa/min/yr)	-0.261 (-0.345; -0.177), p < 0.001	-0.246 (-0.339; -0.152), p < 0.001	-0.295 (-0.579; -0.011), p = 0.042	p = 0.935
CPI	1.571 (0.374; 2.768), p = 0.011	1.071 (-0.241; 2.383), p = 0.110	-0.825 (-4.917; 3.266), p = 0.693	p = 0.514
Annual rate of change (adjusted²)
FVC (l/yr)	0.011 (-0.039; 0.06), p = 0.666	0.015 (-0.039; 0.069), p = 0.577	-0.183 (-0.345; -0.022), p = 0.026	p = 0.070
DLco (mmol/kPa/min/yr)	-0.267 (-0.37; -0.163), p < 0.001	-0.26 (-0.374; -0.146), p < 0.001	-0.334 (-0.68; 0.012), p = 0.058	p = 0.923
CPI	1.682 (0.195; 3.169), p = 0.028	1.229 (-0.426; 2.884), p = 0.146	-2.817 (-8.075; 2.442), p = 0.294	p = 0.273

¹ statistical significance of the interaction between time and GAP index from the linear mixed-effects model; only follow-up visits within 24 months from baseline were included into the model
² adjusted for sex, age and baseline level (FVC, DLCO or CPI, respectively)

ISSN: 1471-2466